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Introduction
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12
inhibitor forms the backbone of secondary prevention follow-
ing acute coronary syndromes (ACS).1,2 Twelve months’ DAPT
post-ACSiswell establishedbutevidence to support prolonged
intensive therapy in high-risk patients following myocardial
infarction (MI) continues to emerge. Prolonged ticagrelor-
based DAPT reduced recurrent MI, stroke or cardiovascular
(CV)death inpatientswithin 1 to3 years of having anMI in the
PEGASUS-TIMI 54 trial.3 A meta-analysis that included
> 33,000 patients with history ofMI frommultiple prolonged
DAPT trials, including the PEGASUS-TIMI 54 study, also
showed prolonged DAPT to result in improved major ischae-
mic events.4 Similarly, in the COMPASS trial,5 dual antithrom-
botic therapy (DATT) with an anticoagulant (very-low-dose
rivaroxaban 2.5 mg twice daily) and aspirin resulted in a
signiﬁcant reduction in major CV events in high-risk stable
coronary artery disease (CAD) patients, two-thirds of whom
hadahistoryofMI. Therewasalsoanumerical reduction inall-
cause mortality that narrowly missed the pre-speciﬁed sig-
niﬁcance threshold (hazard ratio [HR], 0.82; 95% conﬁdence
interval [CI], 0.71–0.96; p ¼ 0.01; threshold p-value for sig-
niﬁcance 0.0025). Both treatment strategies resulted in
increased risk of major bleeding events and, therefore, the
onus is on clinicians to balance the risks of ischaemia and
bleeding. Here, we will consider the evidence for and against
each of these treatment strategies and provide a practical
summary to aid physicians in the decision-making process.
Therapeutic Targets in Arterial Thrombosis
The role of platelets in arterial thrombosis is well established.
As demonstrated in ►Fig. 1, at the site of vascular injury,
platelets adhere to collagen and von Willebrand factor and
these lead to platelet activation. Two key pathways are
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Abstract Antithrombotic treatment is a key component of secondary prevention following acute
coronary syndromes (ACS). Although dual antiplatelet therapy is standard therapy
post-ACS, duration of treatment is the subject of ongoing debate. Prolonged dual
antiplatelet therapy in high-risk patients with history of myocardial infarction reduced
the risk of recurrent myocardial infarction, stroke or cardiovascular death. Similarly, in
patients with stable coronary artery disease, two-thirds of whom had a history of
myocardial infarction, dual antithrombotic therapy with very-low-dose rivaroxaban and
aspirin also resulted in improved ischaemic outcomes. In the absence of head-to-head
comparison, choosing the most appropriate treatment strategy can be challenging,
particularly when it comes to balancing the risks of ischaemia and bleeding. We aim to
review the evidence for currently available antithrombotic treatments and provide a
practical algorithm to aid the decision-making process.
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implicated in amplifying this process, the thromboxane A2
(TxA2) and the adenosine diphosphate (ADP) P2Y12 receptor
pathways. Cyclooxygenase (COX) 1 is key in the production of
TxA2 while ADP is released from platelets’ dense granules.
6
Aspirin targets platelets by irreversible acetylation of COX1
enzyme and currently three oral agents inhibit platelets’ P2Y12
receptors either directly (ticagrelor) or through an active
metabolite (clopidogrel and prasugrel). Studies of DAPT have
demonstrated the pivotal roles of TxA2 and ADP in coronary
thrombosis and, in particular, stent thrombosis.7–9
The protein coagulation arm is also activated following
vascular injury, leading to thrombin production and conse-
quent ﬁbrin formation. Thrombin also activates platelets
through protease-activated receptors (PAR) 1 and 410 and
so anticoagulants have platelet inhibitory effects through
inhibition of thrombin-induced platelet activation, either by
directly inhibiting thrombin or by inhibiting thrombin gen-
eration.11 However, the relative contribution of thrombin to
stent thrombosis remains uncertain in comparison to the
well-established roles of TxA2 andADP. Fibrin clots that resist
lysis independently predict CV death following ACS, indicat-
ing that development of therapies to improve ﬁbrin clot lysis
may be a successful avenue in the future.12
Oral P2Y12 Inhibitors
Multiple landmark clinical trials have established a deﬁnitive
advantage for combining aspirin and a P2Y12 inhibitor for
approximately 12months post-ACS.7–9,13 Prasugrel and tica-
grelor offer more rapid, potent and consistent P2Y12 inhibi-
tion compared with clopidogrel. These properties have
translated into improved outcomes.8,9►Table 1 summarizes
the pharmacodynamics of each of these agents and provides
a summary of appropriate use post-ACS.
Prolonged Dual Antiplatelet Therapy
Time-limited DAPT assumes that thrombotic risk disappears
upon cessation of therapy. However, approximately 1 in 5
patients suffers amajor adverse cardiovascular event (MACE)
within 3 years after cessation of DAPT.14
The CHARISMA trial tested whether clopidogrel-based
DAPT would reduce MACE in > 15,000 patients with multi-
ple atherothrombosis risk factors.15 In this study, DAPT did
not result in a signiﬁcant reduction in ischaemic risk; how-
ever, only less than 50% of patients had documented CV
disease and, among the third who had history of MI, DAPT
appeared to result in improved outcomes.15
Similarly, 30 months’ DAPTwas tested in the DAPT study
in patients undergoing percutaneous coronary intervention
(PCI), the majority of whom were treated for stable CAD. In
this study, prolonged clopidogrel- or prasugrel-based DAPT
resulted in a reduction in MI (2.1% vs. 4.1%; p < 0.001).16
Concerns regarding the numerically higher rates of all-
cause death in the prolonged DAPT group (2% vs. 1.5%,
p ¼ 0.05) and the increased risk of major bleeding (2.5% vs.
1.6%; p ¼ 0.001) have limited a general adoption of such a
strategy. Patients with MI appeared to accrue the greatest
beneﬁt from prolonged DAPT without an increase in all-
cause death.17
Fig. 1 Arterial thrombosis andmodes of action of antithrombotic treatments. Following endothelial disruption, platelets adhere to collagen and
vonWillebrand factor (vWF) in the sub-endothelial matrix. Activated platelets secrete thromboxane A2 (TxA2), adenosine diphosphate (ADP) and
also support the generation of thrombin (IIa). Endothelial disruption and plaque rupture also lead to the expression of tissue factor, triggering
the coagulation cascade. Thrombin plays a more important role in stabilizing the core thrombus through ﬁbrin generation in contrast to ADP and
TxA2, which play key roles in expansion of the platelet-rich thrombus.
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‘a’ denotes activated clotting factors.
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More encouraging results were seen in higher-risk
patients in the PEGASUS-TIMI 54 trial.3 A total of 21,162
patients within 1 to 3 years of having a MI and with
additional risk factors (►Table 2) were randomized to
placebo, ticagrelor 60 mg twice daily or ticagrelor 90 mg
twice daily. Patients with a prior history of stroke or
deemed to have high bleeding risk were excluded. Similar
to high-dose ticagrelor, ticagrelor 60 mg twice daily
reduced the MACE risk compared with placebo (7.77% vs.
9.04%, p < 0.001), including a non-signiﬁcant numerical
reduction in CV mortality in all ticagrelor-treated patients
(2.9% vs. 3.39, p ¼ 0.06), and the similar efﬁcacy of the two
doses of ticagrelor was explained by similarly high levels of
platelet P2Y12 inhibition.
18 Adverse events, primarily dys-
pnoea and bleeding, were more common with ticagrelor
resulting in higher rates of therapy discontinuation, which
may have attenuated the beneﬁts observed with ticagre-
lor.19 Very few patients in the trial had been exposed to
ticagrelor in the past and better tolerance should be
expected if a strategy of continued treatment with aspirin
and ticagrelor is adopted in those who have tolerated this
combination for the initial 12 months after MI.19 Major
bleeding was increased with ticagrelor (90 mg: 2.6%;
60 mg: 2.3%: placebo: 1.1%; p < 0.001 for each comparison
with placebo). It is estimated that 42 MACE would be
prevented per year for every 10,000 patients treated with
ticagrelor 60 mg at the cost of 31 additional non-fatal major
bleeds per year.3 Greater absolute risk reductions were seen
with ticagrelor in patients with either peripheral artery
disease (PAD), chronic kidney disease (CKD) or diabetes
mellitus (DM) as well as those with multi-vessel versus
single-vessel CAD.20–23
A collaborativemeta-analysis that included the sub-groups
of patients with an index event of MI in thienopyridine-based
DAPT studies and patients from the PEGASUS-TIMI 54 study
showed that prolonged DAPT reduced MACE (6.4% vs. 7.5%,
p ¼ 0.001) and reducedCVdeath (2.3%vs. 2.6%,p ¼ 0.03)with
no signiﬁcant increase in non-CV death.4
Table 1 Oral P2Y12 inhibitors
P2Y12 inhibitor Pharmacodynamic properties Appropriate indications post-ACS
Clopidogrel Pro-drug; active metabolite irreversibly blocks
platelet P2Y12 receptors. Complex pharmacoki-
netics leading to variable pharmacodynamic
response with slow onset and offset of action.34
Genetic variants, drug interactions and unknown
factors lead to poor response in up to 30% of
patients35,36
1. When anticoagulation is indicated in addition to
DAPT (e.g. atrial ﬁbrillation, mechanical valves)
2. In thrombolysis-treated STEMI patients
3. When the other P2Y12 inhibitors are either not
available or contraindicated
Prasugrel Pro-drug; active metabolite irreversibly blocks
platelet P2Y12 receptors. Efﬁcient pharmacoki-
netics, starting in the intestines, leading to rapid
platelet inhibition but with similar offset of action
to clopidogrel37
1. Only in PCI-treated ACS patients and either
following angiography or if planned for primary
PCI in STEMI patients
2. Should not be used in patients with history of
stroke, cautioned in those  75 years of age
or < 60 kg
Ticagrelor Direct-acting drug that reversibly blocks platelet
P2Y12 receptors. Similar to prasugrel, its onset of
action is rapid, but, being a reversibly binding
P2Y12 inhibitor, it has more rapid offset of action
38
1. In patients with NSTEMI and high-risk unstable
angina regardless of treatment strategy.
In STEMI patients planned for primary PCI
2. Should not be used in patients with history of
intracranial haemorrhage or those taking strong
CYP3A inducers or inhibitors
3. May be used 2 d post-thrombolysis in STEMI
patients undergoing PCI39
Abbreviations: ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous
coronary intervention; STEMI, ST-elevation myocardial infarction.
Table 2 Key inclusion criteria of PEGASUS-TIMI 54 and COMPASS trials
Inclusion criteria in the PEGASUS-TIMI 54 trial Inclusion criteria in the COMPASS trial (CAD cohort 90%)
MI within 1–3 years
Age  50 years
One additional risk factor:
Age  65 years
Diabetes mellitus
PAD
Multi-vessel CAD
CKD not requiring dialysis
Second previous MI (prior to index MI)
MI within 20 years or multi-vessel CAD regardless of previous
revascularization
Age  65 years or PAD or two additional risk factors:
Current smoking
Diabetes mellitus
CKD—excluding eGFR < 15 mL/min
Heart failure
Non-lacunar ischemic stroke  1 month
Abbreviations: CAD, coronary artery disease; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; MI, myocardial infarction; PAD,
peripheral artery disease.
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Based on this evidence, the European Society of Cardiol-
ogy guidelines give a class IIb recommendation to consider
prolonged therapy in ACS patients who have tolerated 12
months of DAPTwithout bleeding complications. In high-risk
patients (such as those identiﬁed in the PEGASUS-TIMI 54
trial), prolonged ticagrelor-based DAPT is preferred to thie-
nopyridine-based DAPT.24
Anticoagulant Therapy in Secondary
Prevention
The notion of using anticoagulants following ACS for long-
term secondary prevention is far from new. Anticoagulation
with vitamin K antagonists (VKAs) following ACS signiﬁ-
cantly reduced MACE compared with placebo but at the
expense of more major bleeding.25 However, evidence that
DAPT with aspirin and a P2Y12 inhibitor was markedly
superior in the prevention of stent thrombosis to a DATT
approach with aspirin and VKA,26,27 along with the increas-
ing use of PCI for the management of ACS, led to preference
for a DAPT strategy for ACS management.7 Consequently, the
combination of aspirin and VKA was relegated to niche
indication for ACS patients requiring anticoagulant therapy
for other reasons, such as atrial ﬁbrillation.
However, following the development of non-VKA oral
anticoagulants, we learned more about the level of anti-
coagulation that may be needed following ACS in the DAPT
era. High anticoagulation levels with apixaban (same levels
needed for stroke prevention in AF) in addition to DAPT
(aspirin þ clopidogrel) resulted in increased risk of major
bleeds, including intracranial and fatal bleeds, without a
clear beneﬁt of ischaemic risk reduction.28
The novel concept of low anticoagulation levels was tested
in the ATLAS ACS2-TIMI 51 trial.29 Low-dose rivaroxaban (2.5
and 5 mg twice daily), in moderate-to-high-risk ACS patients,
in addition to clopidogrel-basedDAPT, resulted in a signiﬁcant
reduction in MACE (combined rivaroxaban groups 8.9% vs.
placebo 10.7%, p ¼ 0.008). This included a reduction in CV
death with the lower dose of rivaroxaban (2.7% vs. 4.1%,
p ¼ 0.002). The penalty was an increase in non-surgical
bleeding (rivaroxaban 2.5 mg 1.8% vs. rivaroxaban 5 mg 2.4%
vs. placebo 0.6%, p < 0.001 for each comparisonwith placebo)
and intracranial haemorrhage (rivaroxaban 2.5 mg 0.4% vs.
rivaroxaban 5 mg 0.7% vs. placebo 0.2%).29 These results
became available at a time when practice favoured one of
the more reliable P2Y12 inhibitors to clopidogrel and this has
limited adoption of a triple therapy approach.
The effects of substituting aspirin with rivaroxaban
(2.5 mg twice daily) were explored in the GEMINI-ACS-1
study.30 Within 10 days of ACS, 3,037 patients were rando-
mized to either rivaroxaban or aspirin in addition to back-
ground P2Y12 inhibitor therapy (clopidogrel or ticagrelor).
There was no signiﬁcant difference in major bleeding
between rivaroxaban and aspirin. Exploratory analyses
showed a trend for better ischaemic outcomes for those
treated with aspirin and ticagrelor compared with other
combinations. However, this study was only powered to
detect a difference in bleeding endpoints and therefore
efﬁcacy outcomes should only be interpreted as hypoth-
esis-generating results.
In the COMPASS trial,5 27,395 patients with either stable
CAD (90%) or peripheral artery diseasewere randomized to
standard therapy with aspirin, DATT (aspirin þ rivaroxaban
2.5 mg twice daily) or rivaroxaban 5mg twice daily mono-
therapy (►Table 2). Patients at high risk for bleeding, includ-
ing those on DAPT or with coagulopathies, were excluded.
DATT resulted in a signiﬁcant reduction in MACE compared
with aspirin (4.1% vs. 5.4%, respectively, p < 0.001), includ-
ing a reduction in CV death (1.7% vs. 2.2%, p ¼ 0.02) and a
substantial reduction in ischaemic stroke (0.7% vs. 1.4%,
p < 0.001). There was a penalty of increased major bleeding
events with DATT comparedwith aspirinmonotherapy (3.1%
vs. 1.9%, p < 0.001). However, there was no signiﬁcant
increase in fatal or intracranial haemorrhage. Monotherapy
with rivaroxaban 5 mg twice daily did not result in signiﬁ-
cantly improved ischaemic outcomes but increased major
bleeding events.
Choice of Dual Therapy Strategy
The population studied in the COMPASS trial overlaps sub-
stantially with the population studied in the PEGASUS-TIMI
54 trial (►Tables 2 and 3). All patients in PEGASUS had history
of MI (median of 1.7 years prior to randomization) and
Table 3 Baseline patient characteristic in the PEGASUS-TIMI 54
trial and the COMPASS trial
The PEGASUS-TIMI
54 trial
The COMPASS
trial
Age (mean  SD) 65  8 68  8
Female 24% 22%
Smoking 17% 21.5%
Hypertension 78% 75%
Coronary artery
disease
100% 90.5%
Previous MI 100% 62%
Years since MI 1.7 7.1
Peripheral artery
disease
5.5% 27.2%
Diabetes mellitus 32% 38%
Chronic kidney
disease
24% 23%
Previous ischaemic
stroke
0% 4%
Prior CABG NAa 5%
ACE I or ARB 82% 71%
Lipid lowering agent 93% 90%
Abbreviations: ACE I, angiotensin converting enzyme inhibitor; ARB,
angiotensin receptor blocker; CABG, coronary artery bypass surgery;
MI, myocardial infarction; SD, standard deviation.
aIn the PEGASUS-TIMI 54 trial, patients who have had bypass surgery were
excluded unless they had amyocardial infarction following bypass surgery.
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approximately 60% of patients in COMPASS had previous MI
(average 7.1 years). Both trials show that escalation of antith-
rombotic therapy in high-risk stable CAD patients leads to
improved MACE rates, including numerical reductions in CV
death, particularly in individuals at thehighest risk. There is no
head-to-head comparison between the two strategies; how-
ever, there were signals that prolonged DAPT has greater
efﬁcacy at reducing recurrent MI and stent thrombosis as
opposed to greater efﬁcacy for a DATT strategy at reducing
stroke. For instance, there was no signiﬁcant effect of DATTon
stent thrombosis rates in COMPASS, whereas prolonged DAPT
resulted in a signiﬁcant reduction in stent thrombosis in the
PEGASUS-TIMI 54 trial (ticagrelor 90 mg: HR, 0.30, 95% CI:
0.14–0.65; ticagrelor 60 mg: HR, 0.66, 95% CI: 0.37–1.17).31
The different mechanisms of action of ticagrelor and rivarox-
abanmake itcredible that ticagrelorwouldbemoreeffectiveat
preventing occlusive coronary thrombosis, whereas rivarox-
abanmaybemore effective at preventing cardiac thromboem-
bolism due to left atrial appendage thrombosis. Although a
DATTstrategy did not result in overall improvedMACE rates in
patients with CAD and advanced ‘unstable’ heart failure,
similar signals of efﬁcacy in stroke prevention were
observed.32 There could also be differential effects of the
two drugs on vascular inﬂammation and progression of ather-
osclerosis.More research is clearly needed to compare the two
strategies,whichwill help us individualize treatments further.
In the absence of contraindications, ticagrelor is preferred
to clopidogrel inACSpatients.24Amonghigh-riskpatientswho
tolerate ticagrelor 90 mg twice daily for a year, it seems
appropriate to down-titrate to ticagrelor 60 mg twice daily,
in addition to aspirin, for an additional 3 years (or as long as
tolerated in the highest-risk patients). In those who have to
switch antiplatelet therapy during the ﬁrst year (e.g. due to
dyspnoea) and have completed their intended course of DAPT,
starting rivaroxaban 2.5 mg twice daily upon cessation of the
P2Y12 inhibitor (after 12months of DAPT) may be considered.
Fig. 2 Choice of antithrombotic treatment strategy in patients with coronary artery disease. CABG, coronary artery bypass surgery; CAD,
coronary artery disease; CKD, chronic kidney disease (eGFR < 60 mL/min and not requiring dialysis for prolonged DAPT; eGFR < 60 mL/min
and > 15 mL/min for low dose rivaroxaban); DAPT, dual antiplatelet therapy; DATT, dual antithrombotic therapy (aspirin þ rivaroxaban 2.5 mg
twice daily); DM, diabetes mellitus; PAD, peripheral artery disease; MI: myocardial infarction.
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Treatment decisions are easier to implement at the time of
presentationwith ACS and becomemore challenging in those
who have been stable on aspirin monotherapy for years.
However, when encountering stable high-risk CAD patients
(history of ACSwith at least two risk factors such as extensive
CAD,DM,PAD,CKDor recurrentMI)whoare remotefromtheir
ACS event (> 1 year) and have been stable off DAPT, the
addition of rivaroxaban 2.5 mg twice daily may be appropri-
ate. ►Fig. 2 provides a decision-making algorithm to aid
recommendations for antithrombotic therapy in patients
with CAD, particularly those with history of MI.
The riskof bleeding should be balanced against the beneﬁt
of ischaemic risk reduction and additional therapy may be
best avoided in patients at high risk of life-threatening
bleeding. Tools to balance ischaemic and bleeding risk may
be useful and the PRECISE-DAPT risk score was developed to
aid the decision-making process.33 This score, however, has
some limitations. It was based on a study of 14,963 patients
with CAD who underwent PCI (including elective patients)33
and identiﬁed ﬁve predictors of major bleeding events
(increasing age, low creatinine clearance, haemoglobin < 10
g/dL, increased baseline white cell count and history of
spontaneous bleed). Although the derived risk score was
validated in two other PCI-treated cohorts, the utility of the
score was not studied prospectively. Furthermore, some
factors included in the risk score, such as increasing age
and CKD (estimated glomerular ﬁltration rate < 60mL/min/
1.73 m2), were among the inclusion criteria of both the
PEGASUS-TIMI 54 and COMPASS trials and these patients
derived beneﬁt from intensive therapy. Patients with anae-
mia (haemoglobin < 10 g/dL) and those with a history of
spontaneousmajor bleeding were at greatest risk of bleeding
and therefore a strategy of prolonged DAPT or DATT is best
avoided in these scenarios.
Conclusion
Protection against atherothrombosis with DAPT, following
ACS, is well-established and long-term ticagrelor-based
DAPT, in high-risk stable patients with history of MI, has
demonstrated further beneﬁt. Consequently, prolonged
DAPT may be considered in high-risk post-MI patients,
with stronger consideration given to those who are at high
risk of CAD-related death (e.g. extensive multi-vessel CAD)
but deemed at low risk for fatal bleeding (i.e. no history of
intracranial haemorrhage, stroke, bleeding diathesis or
incurable gastrointestinal bleeding). The COMPASS study
results provide support for the use of DATT (aspirin þ rivar-
oxaban 2.5 mg twice daily) in stable patients with history of
MI, PAD and/or multiple risk factors. Among high-risk stable
patients who are not taking DAPT, DATT may be considered
to reduce the risk of further ischaemic events, again with
stronger consideration given to those who are at high risk of
CV death and low risk of fatal bleeding.
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